Fulcrum Therapeutics Reports Recent Business Highlights and Third Quarter 2020 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/28/2026
- Wall St declines as oil spikes after Trump rejects Iran peace proposal
- S&P 500 breadth hits lowest level since dot-com bubble, Goldman says
- Nvidia’s AI dominance funds historic $150 billion buyback
- MongoDB stock drops 15% as CEO Desai resigns for Meta
- Jefferies cuts Roblox to Underperform, says rally is too optimistic
- Bloom Energy shares fall on Oracle project halt
- Oppenheimer sees AI software winners as focus shifts to ROI
- Exclusive-Activist Jana pushes Fiserv to accelerate cost cuts and tap Palantir
- Accenture (ACN) call put ratio 1 call to 1.2 puts into quarter results
- Arm Holdings falls as CFO stock sale weighs on sentiment
Fulcrum Therapeutics Inc. (FULC) Misses Q3 EPS by 5c
November 10, 2020 7:19 AM ESTFulcrum Therapeutics Inc. (NASDAQ: FULC) reported Q3 EPS of ($0.70), $0.05 worse than the analyst estimate of ($0.65).
Third Quarter 2020 Financial Results
Cash Position: As of September 30, 2020, cash, cash equivalents, and marketable securities were $127.0 million, as compared to $96.7 million as of December 31, 2019. Based on its current plans, the Company expects that its existing cash, cash equivalents, and marketable securities will be sufficient to enable it to fund its operating expenses and capital expenditure requirements into the second quarter of 2022.R&D Expenses: Research and development expenses were $15.6 million for the third quarter of 2020, as... More